Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 4 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) Overview | 7 | 1 |
| Therapeutics Development | 8 | 4 |
| Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) Products under Development by Stage of Development | 8 | 1 |
| Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) Products under Development by Therapy Area | 9 | 1 |
| Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) Products under Development by Indication | 10 | 2 |
| Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) Pipeline Products Glance | 12 | 2 |
| Late Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) Products under Development by Companies | 14 | 3 |
| Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) Products under Development by Universities/Institutes | 17 | 2 |
| Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) Therapeutics Assessment | 19 | 7 |
| Assessment by Monotherapy/Combination Products | 19 | 1 |
| Assessment by Mechanism of Action | 20 | 2 |
| Assessment by Route of Administration | 22 | 2 |
| Assessment by Molecule Type | 24 | 2 |
| Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) Companies Involved in Therapeutics Development | 26 | 5 |
| Bellicum Pharmaceuticals, Inc. | 26 | 1 |
| Conatus Pharmaceuticals Inc. | 27 | 1 |
| LG Life Science LTD. | 28 | 1 |
| Novelix Pharmaceuticals, Inc. | 29 | 1 |
| Pharmedartis GmbH | 30 | 1 |
| Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) Drug Profiles | 31 | 21 |
| BPX-501 Drug Profile | 31 | 4 |
| emricasan Drug Profile | 35 | 6 |
| flavokawain A Drug Profile | 41 | 1 |
| Granzyme B/VEGF Drug Profile | 42 | 1 |
| HaA-4 Drug Profile | 43 | 1 |
| nivocasan Drug Profile | 44 | 1 |
| NVX-207 Drug Profile | 45 | 1 |
| plinabulin Drug Profile | 46 | 4 |
| Recombinant Protein to Activate CASP3 and CASP9 for Oncology Drug Profile | 50 | 1 |
| Small Molecule to Activate Caspase 8, 9 for Oncology Drug Profile | 51 | 1 |
| Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) Dormant Projects | 52 | 2 |
| Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) Discontinued Products | 54 | 1 |
| Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) Featured News &Press Releases | 55 | 14 |
| May 26, 2016: American Society of Clinical Oncology Selects BeyondSpring Abstract on Neutropenia Mitigation with Plinabulin Use for Publication | 55 | 1 |
| May 19, 2016: Bellicum Announces Data Presentation of BPX-501 at the European Hematology Association | 56 | 1 |
| May 12, 2016: BeyondSpring Chief Medical Officer Served as Panelist at NewYorkBIO | 56 | 1 |
| May 04, 2016: Conatus Extends Positive Results with Emricasan in Phase 2 Liver Cirrhosis Clinical Trial | 56 | 2 |
| Apr 18, 2016: Conatus Late Breaker Oral Presentation at EASL Details Phase 2 Liver Cirrhosis Trial Three-month Data | 58 | 2 |
| Apr 05, 2016: Bellicum Pharmaceuticals Announces BPX-501 Clinical Data Updates | 60 | 1 |
| Mar 30, 2016: Conatus Pharmaceuticals Announces Late Breaker Oral Presentation on Emricasan at EASL Meeting | 60 | 1 |
| Feb 24, 2016: BeyondSpring Pharmaceuticals to Present Plinabulin at 4th Annual Cancer Biopartnering &Investment Forum in NYC | 61 | 1 |
| Feb 22, 2016: FDA Grants Orphan Drug Designation to Bellicum s BPX-501 for the Treatment of Immunodeficiency and GvHD Following Stem Cell Transplant | 62 | 1 |
| Feb 08, 2016: BeyondSpring Pharmaceuticals Data Indicating Plinabulin Enhances Immune Response Provides Basis for Planned Phase I/II Combination Trial in NSCLC | 62 | 1 |
| Feb 03, 2016: FDA Grants Conatus Fast Track Designation for Development of Emricasan in NASH Cirrhosis | 63 | 1 |
| Jan 11, 2016: Conatus Initiates Phase 2b ENCORE-NF Clinical Trial of Emricasan in Patients With NASH Fibrosis | 64 | 1 |
| Jan 07, 2016: BeyondSpring Pharmaceuticals to Present at 8th Annual Biotech Showcase | 65 | 1 |
| Jan 05, 2016: Conatus Achieves Positive Results with Emricasan in Initial Stage of Phase 2 Liver Cirrhosis Clinical Trial | 66 | 1 |
| Jan 05, 2016: BeyondSpring Pharmaceuticals to Present Plinabulin-Immune System Interactions at AACR s 2016 Tumor Microenvironment Special Conference | 67 | 2 |
| Appendix | 69 | 2 |
| Methodology | 69 | 1 |
| Coverage | 69 | 1 |
| Secondary Research | 69 | 1 |
| Primary Research | 69 | 1 |
| Expert Panel Validation | 69 | 1 |
| Contact Us | 69 | 1 |
| Disclaimer | 70 | 1 |